149 related articles for article (PubMed ID: 36847041)
1. Computational study of novel natural inhibitors targeting Kirsten rat sarcoma viral oncogene homolog G12C.
Yang W; Ge J; Yuan M; Li J; Pan L; Ren J; Dou G; Yang L; Zhou Y; Xie H; Wang X; Hu H
Anticancer Drugs; 2023 Jun; 34(5):609-619. PubMed ID: 36847041
[TBL] [Abstract][Full Text] [Related]
2. Novel natural inhibitors targeting KRAS G12C by computational study.
Jiang Y; Chen W; Wang X; Zhou B; Xie H; Hou Y; Guo Z; Yu B; Zhong S; Su X
Anticancer Drugs; 2022 Oct; 33(9):779-788. PubMed ID: 35980001
[TBL] [Abstract][Full Text] [Related]
3. Drug Repurposing against KRAS Mutant G12C: A Machine Learning, Molecular Docking, and Molecular Dynamics Study.
Srisongkram T; Weerapreeyakul N
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614109
[TBL] [Abstract][Full Text] [Related]
4. Recent progress in targeting KRAS mutant cancers with covalent G12C-specific inhibitors.
Rathod LS; Dabhade PS; Mokale SN
Drug Discov Today; 2023 May; 28(5):103557. PubMed ID: 36934967
[TBL] [Abstract][Full Text] [Related]
5. Complete response to nivolumab in Kirsten rat sarcoma virus oncogene KRAS-G12C mutant metastatic lung adenocarcinoma: a case report.
Boby JM; Mohd Ghazali NN; Mani A; George M
J Med Case Rep; 2022 Nov; 16(1):420. PubMed ID: 36329437
[TBL] [Abstract][Full Text] [Related]
6. Pharmacophoric analogs of sotorasib-entrapped KRAS G12C in its inactive GDP-bound conformation: covalent docking and molecular dynamics investigations.
Oyedele AK; Ogunlana AT; Boyenle ID; Ibrahim NO; Gbadebo IO; Owolabi NA; Ayoola AM; Francis AC; Eyinade OH; Adelusi TI
Mol Divers; 2023 Aug; 27(4):1795-1807. PubMed ID: 36271195
[TBL] [Abstract][Full Text] [Related]
7. Establishing the Role of Iridoids as Potential Kirsten Rat Sarcoma Viral Oncogene Homolog G12C Inhibitors Using Molecular Docking; Molecular Docking Simulation; Molecular Mechanics Poisson-Boltzmann Surface Area; Frontier Molecular Orbital Theory; Molecular Electrostatic Potential; and Absorption, Distribution, Metabolism, Excretion, and Toxicity Analysis.
Alamri MA; Alawam AS; Alshahrani MM; Kawsar SMA; Prinsa ; Saha S
Molecules; 2023 Jun; 28(13):. PubMed ID: 37446713
[TBL] [Abstract][Full Text] [Related]
8. Targeting KRAS in Colorectal Cancer.
Wang C; Fakih M
Curr Oncol Rep; 2021 Feb; 23(3):28. PubMed ID: 33582927
[TBL] [Abstract][Full Text] [Related]
9. Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.
Zheng X; Luo J; Liu W; Ashby CR; Chen ZS; Lin L
Drugs Today (Barc); 2022 Apr; 58(4):175-185. PubMed ID: 35412531
[TBL] [Abstract][Full Text] [Related]
10. KRAS G12C-Mutant Non-Small Cell Lung Cancer: Biology, Developmental Therapeutics, and Molecular Testing.
Veluswamy R; Mack PC; Houldsworth J; Elkhouly E; Hirsch FR
J Mol Diagn; 2021 May; 23(5):507-520. PubMed ID: 33618059
[TBL] [Abstract][Full Text] [Related]
11. Prediction of KRAS
Srisongkram T; Khamtang P; Weerapreeyakul N
J Mol Graph Model; 2023 Jul; 122():108466. PubMed ID: 37058997
[TBL] [Abstract][Full Text] [Related]
12. The prognostic value of Kirsten rat sarcoma viral oncogene homolog mutations in resected lung adenocarcinoma differs according to clinical features.
Ma Z; Zhang Y; Deng C; Fu F; Deng L; Li Y; Chen H
J Thorac Cardiovasc Surg; 2022 Jan; 163(1):e73-e85. PubMed ID: 32739163
[TBL] [Abstract][Full Text] [Related]
13. Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC).
Parums DV
Med Sci Monit; 2022 Nov; 28():e938746. PubMed ID: 36317327
[TBL] [Abstract][Full Text] [Related]
14. Identification of
Thein KZ; Biter AB; Banks KC; Duda AW; Saam J; Roszik J; Janku F; Skoulidis F; Heymach JV; Kopetz S; Meric-Bernstam F; Hong DS
JCO Precis Oncol; 2022 Jul; 6():e2100547. PubMed ID: 35862868
[TBL] [Abstract][Full Text] [Related]
15.
Jones GD; Caso R; Tan KS; Mastrogiacomo B; Sanchez-Vega F; Liu Y; Connolly JG; Murciano-Goroff YR; Bott MJ; Adusumilli PS; Molena D; Rocco G; Rusch VW; Sihag S; Misale S; Yaeger R; Drilon A; Arbour KC; Riely GJ; Rosen N; Lito P; Zhang H; Lyden DC; Rudin CM; Jones DR; Li BT; Isbell JM
Clin Cancer Res; 2021 May; 27(9):2604-2612. PubMed ID: 33593884
[TBL] [Abstract][Full Text] [Related]
16. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
[TBL] [Abstract][Full Text] [Related]
17. KRAS G12C mutated advanced non-small cell lung cancer (NSCLC): Characteristics, treatment patterns and overall survival from a Danish nationwide observational register study.
Frost MG; Jensen KJ; Gotfredsen DR; Sørensen AMS; Ankarfeldt MZ; Louie KS; Sroczynski N; Jakobsen E; Andersen JL; Jimenez-Solem E; Petersen TS
Lung Cancer; 2023 Apr; 178():172-182. PubMed ID: 36868178
[TBL] [Abstract][Full Text] [Related]
18. KRAS Inhibitors- yes but what next? Direct targeting of KRAS- vaccines, adoptive T cell therapy and beyond.
Nagasaka M; Potugari B; Nguyen A; Sukari A; Azmi AS; Ou SI
Cancer Treat Rev; 2021 Dec; 101():102309. PubMed ID: 34715449
[TBL] [Abstract][Full Text] [Related]
19. Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors.
Stites EC; Shaw AS
CPT Pharmacometrics Syst Pharmacol; 2018 May; 7(5):342-351. PubMed ID: 29484842
[TBL] [Abstract][Full Text] [Related]
20. KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma.
Nadal E; Chen G; Prensner JR; Shiratsuchi H; Sam C; Zhao L; Kalemkerian GP; Brenner D; Lin J; Reddy RM; Chang AC; Capellà G; Cardenal F; Beer DG; Ramnath N
J Thorac Oncol; 2014 Oct; 9(10):1513-22. PubMed ID: 25170638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
